Progress Update on MedMira’s COVID-19 Product Family
HALIFAX, Nova Scotia, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a...
Month: January 2021
Haymarket Media Group Expands US Board as It Enters Its Next Phase of Rapid Growth
Haymarket Media Group bolsters its US Board, including the appointment of two national leaders in oncology and digital health technology,...
Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE...
Nationwide Medication Savings Leader Prescription Hope Introduces Work-from-Home Positions
STUART, FL / ACCESSWIRE / January 29, 2021 / Prescription Hope, one of the largest patient assistance program administrators in...
Novamind to Present at Canaccord Genuity Conference: “New Paradigms & Treatment Approaches in Mental Health”
Conference highlights industry leaders and innovators in the psychedelic therapy space and features Michael Pollan, author of New York Times...
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and...
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
Phase 2 Confirmed Objective Response Rate is 93% (95% CI: 68-100); Pooled Phase 1/2 Confirmed Objective Response Rate is 91%...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that...
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women...
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it...
Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts
Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial SuccessHIGHLANDS RANCH, Colo.,...
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
VANCOUVER and MINNEAPOLIS, Jan. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
In accordance with its long-term incentive program ("LTIP") Ambu A/S has allocated performance share units (PSUs) to members of the Executive...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
In accordance with its long-term incentive program ("LTIP") Ambu A/S has allocated performance share units (PSUs) to members of the Executive...
Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility
TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) is pleased to announce that it...
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021 CAMBRIDGE, Mass....
Launch of Long-Term Incentive Plan
In accordance with the Remuneration Policy approved at the annual general meeting on 17 December 2019, Ambu A/S has today...
OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs
WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker...
MediPharm Labs Appoints New Chief Financial Officer
TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”)...
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a...
